CAJ | 학술논문

肺癌是世界上发病率和病死率最高的肿瘤。低剂量 CT(LDCT)筛查肺癌能显著提高肺癌早期诊断率,并能降低肺癌高危人群的病死率。目前 LDCT 筛查肺癌争议主要有：假阳性过高带来的不必要的有创检查,LDCT 的辐射问题,费用问题,以及筛查的目标人群尚不明确。优化筛查方案,并将LDCT 同其他手段联合起来,能在降低假阳性率的同时提高早期诊断率,最终提高肺癌患者的生存率。
폐암시세계상발병솔화병사솔최고적종류。저제량 CT(LDCT)사사폐암능현저제고폐암조기진단솔,병능강저폐암고위인군적병사솔。목전 LDCT 사사폐암쟁의주요유：가양성과고대래적불필요적유창검사,LDCT 적복사문제,비용문제,이급사사적목표인군상불명학。우화사사방안,병장LDCT 동기타수단연합기래,능재강저가양성솔적동시제고조기진단솔,최종제고폐암환자적생존솔。
The morbidity and mortality of lung cancer are the highest in malignant tumor around the world.Low-dose CT (LDCT)screening may remarkably increase the early diagnosis rate of lung cancer and may decrease the mortality of high risk population.Current controversy about LDCT screening includes:the high false positive rate leading to unnecessary invasive procedure,CT radiation,high cost,and the uncertain of target population.Optimizing LDCT screening procedure and combining LDCT with other methods may decrease the false positive rate as well as increase sensitivity,ultimately increase the survival of lung cancer patients.